Reparixin

DRUG12 trials

Sponsors

Dompe' Farmaceutici S.p.A., Dompé Farmaceutici S.p.A, Icahn School of Medicine at Mount Sinai

Conditions

Acute Respiratory Distress SyndromeBreast CancerEarly Allograft DysfunctionFatigueInfectious PneumoniaIschemia-reperfusion Injury in Liver TransplantIslet Transplantation in Diabetes Mellitus Type 1Locally Advanced or Metastatic Breast Cancer

Phase 2

Reparixin in Pancreatic Islet Transplantation

CompletedNCT01220856

Dompé Farmaceutici S.p.APancreatic Islet Transplantation in Type 1 Diabetes Mellitus

Start: 2010-07-28End: 2013-04-30Updated: 2021-03-11

Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

TerminatedNCT01861054

Dompé Farmaceutici S.p.ABreast Cancer

Start: 2013-02-28End: 2016-03-01Updated: 2021-05-14

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

CompletedNCT01967888

Dompé Farmaceutici S.p.APancreatectomy for Chronic Pancreatitis

Start: 2014-02-28End: 2018-01-31Updated: 2023-11-02

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

CompletedNCT02370238

Dompé Farmaceutici S.p.AMetastatic Breast Cancer

Start: 2015-07-29End: 2020-03-23Updated: 2022-09-16

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

TerminatedNCT03031470

Dompé Farmaceutici S.p.AEarly Allograft Dysfunction, Ischemia-reperfusion Injury in Liver Transplant

Start: 2015-03-10End: 2017-03-31Updated: 2025-01-07

Reparixin in COVID-19 Pneumonia - Efficacy and Safety

TerminatedNCT04794803

Dompé Farmaceutici S.p.ASevere Pneumonia

Start: 2020-05-05End: 2021-02-02Updated: 2024-01-08

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

WithdrawnNCT05212701

Dompé Farmaceutici S.p.AFatigue, Locally Advanced or Metastatic Breast Cancer

Start: 2022-04-19End: 2024-07-31Updated: 2024-04-30

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

RecruitingNCT05835466

Icahn School of Medicine at Mount SinaiMyelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)

Start: 2023-07-24End: 2028-12-01Target: 10Updated: 2026-05-06

Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acute Respiratory Distress Syndrome (RESPIRATIO)

CompletedCTIS2024-512621-88-00

Dompe' Farmaceutici S.p.A.Acute Respiratory Distress Syndrome

Start: 2022-12-06End: 2025-04-14Target: 15Updated: 2025-01-31

Phase 3

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

CompletedNCT01817959

Dompé Farmaceutici S.p.AIslet Transplantation in Diabetes Mellitus Type 1

Start: 2012-10-31End: 2017-12-31Updated: 2024-01-03

Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

CompletedNCT04878055

Dompé Farmaceutici S.p.APneumonia, Viral

Start: 2021-02-14End: 2021-10-31Updated: 2024-06-13

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

TerminatedNCT05254990

Dompé Farmaceutici S.p.AInfectious Pneumonia, Severe COVID-19

Start: 2022-04-27End: 2024-09-27Updated: 2026-02-24

Related Papers

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Blood2025-11-03

Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.

2024-12-204 citations

Neutrophils as potential therapeutic targets for breast cancer.

2023-11-1433 citations

Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study.

2023-10-058 citations

A phase 3 study to evaluate the efficacy and safety of reparixin in severe COVID-19 pneumonia

10.01 - Respiratory infections and bronchiectasis2022-09-044 citations

A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia.

2022-05-2624 citations

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).

2021-09-0363 citations

Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation

Cell Transplantation2021-01-0111 citations

Abstract P3-11-07: A randomized phase II trial of reparixin, a CXCR1 inhibitor, in combination with paclitaxel in the treatment of mTNBC

Cancer Research2020-02-153 citations

Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes

Diabetes Care2020-02-0449 citations

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

2020-01-1086 citations

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

Clinical Cancer Research2017-05-24234 citations

Abstract CT057: A single-arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery

Cancer Research2016-07-157 citations

Abstract C22: A phase Ib study of the CXCR1/2 inhibitor Reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer - final analysis

Molecular Cancer Therapeutics2015-12-012 citations